Long-term trends in adherence to antiretroviral therapy from start of HAART

AIDS

Volumn 24, Issue 8, 2010, Pages 1153-1162

  Cambiano, Valentina ^a   Lampe, Fiona C ^a   Rodger, Alison J ^a,b   Smith, Colette J ^a   Geretti, Anna M ^b   Lodwick, Rebecca K ^a   Puradiredja, Dewi I ^a   Johnson, Margaret ^b   Swaden, Leonie ^b   Phillips, Andrew N ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^b ROYAL FREE HOSPITAL   (United Kingdom)

Author keywords

Antiretroviral drugs; Drug adherence; HAART; HIV infection; Prescription; Trend

Indexed keywords

2',3' DIDEOXY 2' FLUOROADENOSINE; ABACAVIR; ABACAVIR PLUS LAMIVUDINE PLUS ZIDOVUDINE; ADEFOVIR; ANTIRETROVIRUS AGENT; ATAZANAVIR PLUS RITONAVIR; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; NELFINAVIR; NEVIRAPINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; RITONAVIR PLUS SAQUINAVIR; SAQUINAVIR; STAVUDINE; TENOFOVIR; ZALCITABINE;

ADULT; AGE; ARTICLE; COMBINATION CHEMOTHERAPY; DEATH; FEMALE; FOLLOW UP; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; PREDICTOR VARIABLE; PRESCRIPTION; PRIORITY JOURNAL; TREATMENT FAILURE; UNITED KINGDOM;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MALE; MEDICATION ADHERENCE; TREATMENT OUTCOME; VIRAL LOAD;

EID: 77951877350     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e32833847af     Document Type: Article

References (51)

1. Hogg RS, Heath KV, Yip B, Craib KJ, O'Shaughnessy MV, Schechter MT, et al. Improved survival among HIV-infected individuals following initiation of antiretroviral therapy. JAMA 1998; 279:450-454. (Pubitemid 28082255)
2. Palella FJ Jr, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998; 338:853-860. (Pubitemid 128751297)
3. Lampe FC, Smith CJ, Madge S, Kinloch-de LS, Tyrer M, Sabin CA, et al. Success of clinical care for human immunodeficiency virus infection according to demographic group among sexually infected patients in a routine clinic population, 1999 to 2004. Arch Intern Med 2007; 167:692-700. (Pubitemid 46598462)
4. May MT, Sterne JA, Costagliola D, Sabin CA, Phillips AN, Justice AC, et al. HIV treatment response and prognosis in Europe and North America in the first decade of highly active antiretroviral therapy: a collaborative analysis. Lancet 2006; 368:451-458.
5. Mannheimer S, Friedland G, Matts J, Child C, Chesney M. The consistency of adherence to antiretroviral therapy predicts biologic outcomes for human immunodeficiency virus-infected persons in clinical trials. Clin Infect Dis 2002; 34:1115-1121. (Pubitemid 34289685)
6. Liu H, Miller LG, Hays RD, Golin CE, Wu T, Wenger NS, et al. Repeated measures longitudinal analyses of HIV virologic response as a function of percentage adherence, dose timing, genotypic sensitivity, and other factors. J Acquir Immune Defic Syndr 2006; 41:315-322.
7. Paterson DL, Swindells S, Mohr J, Brester M, Vergis EN, Squier C, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med 2000; 133:21-30. (Pubitemid 30432540)
8. Bangsberg DR, Charlebois ED, Grant RM, Holodniy M, Deeks SG, Perry S, et al. High levels of adherence do not prevent accumulation of HIV drug resistance mutations. AIDS 2003; 17:1925-1932. (Pubitemid 37070278)
9. McNabb J, Ross JW, Abriola K, Turley C, Nightingale CH, Nicolau DP. Adherence to highly active antiretroviral therapy predicts virologic outcome at an inner-city human immunodeficiency virus clinic. Clin Infect Dis 2001; 33:700-705. (Pubitemid 32762944)
10. Wood E, Hogg RS, Yip B, Harrigan PR, O'Shaughnessy MV, Montaner JS. The impact of adherence on CD4 cell count responses among HIV-infected patients. J Acquir Immune Defic Syndr 2004; 35:261-268. (Pubitemid 38280651)
11. Mayers DL. Drug-resistant HIV-1: the virus strikes back. JAMA 1998; 279:2000-2002.
12. Wainberg MA, Friedland G. Public health implications of antiretroviral therapy and HIV drug resistance. JAMA 1998; 279:1977-1983. (Pubitemid 28298277)
13. Hogg RS, Heath K, Bangsberg D, Yip B, Press N, O'Shaughnessy MV, et al. Intermittent use of triple-combination therapy is predictive of mortality at baseline and after 1 year of follow-up. AIDS 2002; 16:1051-1058. (Pubitemid 34499429)
14. Garcia de OP, KnobelH,CarmonaA, GuelarA,Lopez-Colomes JL, Cayla JA. Impact of adherence and highly active antiretro-viral therapy on survival in HIV-infected patients. J Acquir Immune Defic Syndr 2002; 30:105-110. (Pubitemid 34506694)
15. Wood E, Hogg RS, Yip B, Harrigan PR, O'Shaughnessy MV, Montaner JS. Effect of medication adherence on survival of HIV-infected adults who start highly active antiretroviral therapy when the CD4R cell count is 0.200 to 0.350 T 10(9) cells/L. Ann Intern Med 2003; 139:810-816.
16. Moss AR, Hahn JA, Perry S, Charlebois ED, Guzman D, Clark RA, et al. Adherence to highly active antiretroviral therapy in the homeless population in San Francisco: a prospective study. Clin Infect Dis 2004; 39:1190-1198. (Pubitemid 40169319)
17. Lucas GM, Gebo KA, Chaisson RE, Moore RD. Longitudinal assessment of the effects of drug and alcohol abuse on HIV-1 treatment outcomes in an urban clinic. AIDS 2002; 16:767-774.
18. Godin G, Cote J, Naccache H, Lambert LD, Trottier S. Prediction of adherence to antiretroviral therapy: a one-year longitudinal study. AIDS Care 2005; 17:493-504. (Pubitemid 40663209)
19. Lima VD, Harrigan R, Bangsberg DR, Hogg RS, Gross R, Yip B, et al. The combined effect of modern highly active antiretro-viral therapy regimens and adherence on mortality over time. J Acquir Immune Defic Syndr 2009; 50:529-536.
20. Tesoriero J, French T, Weiss L, Waters M, Finkelstein R, Agins B. Stability of adherence to highly active antiretroviral therapy over time among clients enrolled in the treatment adherence demonstration project. J Acquir Immune Defic Syndr 2003; 33:484-493. (Pubitemid 36886077)
21. Carrieri P, Cailleton V, Le Moing V, Spire B, Dellamonica P, Bouvet E, et al. The dynamic of adherence to highly active antiretroviral therapy: results from the French National APRO-CO cohort. J Acquir Immune Defic Syndr 2001; 28:232-239. (Pubitemid 33055448)
22. Halkitis P, Palamar J, Mukherjee P. Analysis of HIV medication adherence in relation to person and treatment characteristics using hierarchical linear modeling. AIDS Patient Care STDS 2008; 22:323-335. (Pubitemid 351562967)
23. Stone VE, Clarke J, Lovell J, Steger KA, Hirschhorn LR, Boswell S, et al. HIV/AIDS patients' perspectives on adhering to regimens containing protease inhibitors. J Gen Intern Med 1998; 13:586-593. (Pubitemid 28424029)
24. Bangsberg DR, Perry S, Charlebois ED, Clark RA, Roberston M, Zolopa AR, et al. Nonadherence to highly active antiretroviral therapy predicts progression to AIDS. AIDS 2001; 15:1181-1183. (Pubitemid 32549871)
25. Hinkin CH, Hardy DJ, Mason KI, Castellon SA, Durvasula RS, Lam MN, et al. Medication adherence in HIV-infected adults: effect of patient age, cognitive status, and substance abuse. AIDS 2004; 18 (Suppl 1):S19-S25.
26. Singh N, Squier C, Sivek C, Wagener M, Nguyen MH, Yu VL. Determinants of compliance with antiretroviral therapy in patients with human immunodeficiency virus: prospective assessment with implications for enhancing compliance. AIDS Care 1996; 8:261-269. (Pubitemid 26164414)
27. Gifford AL, Bormann JE, Shively MJ, Wright BC, Richman DD, Bozzette SA. Predictors of self-reported adherence and plasma HIV concentrations in patients on multidrug anti-retroviral regimens. J Acquir Immune Defic Syndr 2000; 23:386-395.
28. Kleeberger CA, Phair JP, Strathdee SA, Detels R, Kingsley L, Jacobson LP. Determinants of heterogeneous adherence to HIV-antiretroviral therapies in the Multicenter AIDS Cohort Study. J Acquir Immune Defic Syndr 2001; 26:82-92. (Pubitemid 32115053)
29. Altice FL, Mostashari F, Friedland GH. Trust and the acceptance of and adherence to antiretroviral therapy. J Acquir Immune Defic Syndr 2001; 28:47-58. (Pubitemid 33104527)
30. Spire B, Duran S, Souville M, Leport C, Raffi F, Moatti JP. Adherence to highly active antiretroviral therapies (HAART) in HIV-infected patients: from a predictive to a dynamic approach. Soc Sci Med 2002; 54:1481-1496. (Pubitemid 34309013)
31. Gordillo V, del Amo J, Soriano V, Gonzalez-Lahoz J. Sociodemographic and psychological variables influencing adherence to antiretroviral therapy. AIDS 1999; 13:1763-1769. (Pubitemid 30015725)
32. Ickovics JR, Cameron A, Zackin R, Bassett R, Chesney M, Johnson VA, et al. Consequences and determinants of adherence to antiretroviral medication: results from Adult AIDS Clinical Trials Group protocol 370. Antivir Ther 2002; 7:185-193. (Pubitemid 36427144)
33. Horne R, Cooper V, Gellaitry G, Date HL, Fisher M. Patients' perceptions of highly active antiretroviral therapy in relation to treatment uptake and adherence: the utility of the necessity-concerns framework. J Acquir Immune Defic Syndr 2007; 45:334-341. (Pubitemid 47012382)
34. Chesney MA. Factors affecting adherence to antiretroviral therapy. Clin Infect Dis 2000; 30 (Suppl 2):S171-S176. (Pubitemid 32268984)
35. Sabin CA, Lampe FC, Chaloner C, Madge SJ, Lipman MC, Youle M, et al. An audit of antiretroviral treatment use in HIV-infected patients in a London clinic: the limitations of observational databases when auditing antiretroviral treatment use. HIV Med 2003; 4:87-93. (Pubitemid 36582290)
36. Grossberg R, Zhang Y, Gross R. A time-to-prescription-refill measure of antiretroviral adherence predicted changes in viral load in HIV. J Clin Epidemiol 2004; 57:1107-1110. (Pubitemid 39451804)
37. Gardner EM, Burman WJ, Maravi ME, Davidson AJ. Selective drug taking during combination antiretroviral therapy in an unselected clinic population. J Acquir Immune Defic Syndr 2005; 40:294-300.
38. Cambiano V, Lampe FC, Rodger AJ, Smith CJ, Geretti AM, Lodwick R, et al. Use of a prescription-based measure of antiretroviral therapy adherence to predict viral rebound in HIV infected individuals with viral suppression. HIV Med (in press).
39. Gross R, Bilker WB, Friedman HM, Strom BL. Effect of adherence to newly initiated antiretroviral therapy on plasma viral load. AIDS 2001; 15:2109-2117. (Pubitemid 33101818)
40. Liu H, Golin CE, Miller LG, Hays RD, Beck CK, Sanandaji S, et al. A comparison study of multiple measures of adherence to HIV protease inhibitors. Ann Intern Med 2001; 134:968-977. (Pubitemid 32466236)
41. Lodwick RK, Smith CJ, Youle M, Lampe FC, Tyrer M, Bhagani S, et al. Stability of antiretroviral regimens in patients with viral suppression. AIDS 2008; 22:1039-1046. (Pubitemid 351769742)
42. Bangsberg DR. Less than 95% adherence to nonnucleoside reverse-transcriptase inhibitor therapy can lead to viral suppression. Clin Infect Dis 2006; 43:939-941.
43. Gulick RM. Adherence to antiretroviral therapy: how much is enough? Clin Infect Dis 2006; 43:942-944. (Pubitemid 44435527)
44. Shuter J, Sarlo JA, Kanmaz TJ, Rode RA, Zingman BS. HIV-infected patients receiving lopinavir/ritonavir-based antiretro-viral therapy achieve high rates of virologic suppression despite adherence rates less than 95%. J Acquir Immune Defic Syndr 2007; 45:4-8. (Pubitemid 46684437)
45. Martin M, del Cacho E, Codina C, Tuset M, De Lazzari E, Mallolas J, et al. Relationship between adherence level, type of the antiretroviral regimen, and plasma HIV type 1 RNA viral load: a prospective cohort study. AIDS Res Hum Retroviruses 2008; 24:1263-1268.
46. Pillay D. The emergence and epidemiology of resistance in the nucleoside-experienced HIV-infected population. Antivir Ther 2001; 6 (Suppl 3):15-24. (Pubitemid 32938760)
47. Kozal MJ, Amico KR, Chiarella J, Cornman D, Fisher W, Fisher J, et al. HIV drug resistance and HIV transmission risk behaviors among active injection drug users. J Acquir Immune Defic Syndr 2005; 40:106-109. (Pubitemid 41233214)
48. Barroso PF, Schechter M, Gupta P, Bressan C, Bomfim A, Harrison LH. Adherence to antiretroviral therapy and persistence of HIV RNA in semen. J Acquir Immune Defic Syndr 2003; 32:435-440 (Pubitemid 36363159)
49. The UK Collaborative Group for HIV and STI Surveillance. Mapping the issues: HIV and other sexually transmitted infections in the United Kingdom. London: HPA Centre for Infections; 2005.
50. Israelski D, Gore-Felton C, Power R, Wood MJ, Koopman C. Sociodemographic characteristics associated with medical appointment adherence among HIV-seropositive patients seeking treatment in a county outpatient facility. Prev Med 2001; 33:470-475. (Pubitemid 33035790)
51. Wutoh AK, Brown CM, Kumoji EK, Daftary MS, Jones T, Barnes NA, et al. Antiretroviral adherence and use of alternative therapies among older HIV-infected adults. J Natl Med Assoc 2001; 93:243-250. (Pubitemid 33613246)